Quanterix Q3 revenue rises 6.3% sequentially
QTRX•Quanterix’s third-quarter revenue rose 6.3% sequentially but fell year over year, while its net loss narrowed 36% to $21.6 million. The company narrowed its 2026 revenue outlook to $142 million-$146 million and expects adjusted gross margin of 48%-50%.
1. Quarterly results
Quanterix reported third-quarter revenue growth of 6.3% sequentially, although revenue fell from a year earlier. Its net loss narrowed 36% year over year to $21.59 million. Product revenue was $25.19 million, gross profit was $13.5 million and operating expenses were $36 million.
2. Outlook and growth drivers
The company narrowed its 2026 revenue outlook to $142 million-$146 million. It expects adjusted gross margin of 48%-50% and to end 2026 with about $70 million in cash and no debt. Quanterix attributed sequential growth across its businesses to a commercial reorganization, two new partnerships with regional clinical labs, expanded Alzheimer’s test coverage and regulatory approvals in China through partnerships with Innovita Biological Technology.
